| PARP inhibitors in the treatment of early breast cancer: the step beyond? A Gonçalves, A Bertucci, F Bertucci Cancers 12 (6), 1378, 2020 | 36 | 2020 |
| PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma E Billon, P Finetti, A Bertucci, P Niccoli, D Birnbaum, E Mamessier, ... Oncoimmunology 8 (11), e1655362, 2019 | 28 | 2019 |
| Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements A Bertucci, F Bertucci, A Gonçalves Cancers 15 (5), 1416, 2023 | 19 | 2023 |
| Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program D Bello Roufai, A Goncalves, T De La Motte Rouge, S Akla, C Blonz, ... Oncogene 42 (23), 1951-1956, 2023 | 13 | 2023 |
| PELICAN-IPC 2015-016/Oncodistinct-003: a prospective, multicenter, open-label, randomized, non-comparative, phase ii study of pembrolizumab in combination with neo adjuvant EC … A Bertucci, F Bertucci, C Zemmour, F Lerebours, JY Pierga, C Levy, ... Frontiers in Oncology 10, 575978, 2020 | 10 | 2020 |
| Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution … A Bertucci, L Cartier, A Rollet, R Boustany, W Hilgers Cancers 15 (7), 2069, 2023 | 4 | 2023 |
| Primary central nervous system lymphoma (PCNSL) in older patients A Bertucci, V Harlay, O Chinot, E Tabouret Current Opinion in Oncology 35 (5), 373-381, 2023 | 3 | 2023 |
| GD3 ganglioside is a promising therapeutic target for glioma patients V Hein, N Baeza-Kallee, A Bertucci, C Colin, A Tchoghandjian, ... Neuro-Oncology Advances, vdae038, 2024 | 1 | 2024 |
| Primary central nervous system lymphoma with initial spinal cord involvement (PCNSL-SC) is a rare entity: 4 case reports and review of literature V Harlay, C Campello, C Bequet, G Petrirena, M Barrie, R Appay, I Arnoux, ... Revue Neurologique 180 (3), 224-229, 2024 | 1 | 2024 |
| Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program. D Bello, A Bertucci, T De La Motte Rouge, C Blonz, S Akla, J Grenier, ... Journal of Clinical Oncology 39 (15_suppl), 1064-1064, 2021 | 1 | 2021 |
| A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of … P Grassi, W Hilgers, R Boissier, A Bertucci, D Bruyat, F Duffaud, F Enoch, ... Clinical Genitourinary Cancer 23 (1), 102283, 2025 | | 2025 |
| Metabolic adaptation of myeloid cells in the glioblastoma microenvironment N Essakhi, A Bertucci, N Baeza-Kallee, C Colin, R Lavignolle-Heguy, ... Frontiers in Immunology 15, 1431112, 2024 | | 2024 |
| Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma V HARLAY, A BERTUCCI, C BOUCARD, G PETRIRENA, C CAMPELLO, ... Anticancer Research 44 (10), 4427-4433, 2024 | | 2024 |
| Prognostic value of Beta 2-Microglobulinin in cerebrospinal fluid in primary central nervous system lymphoma. A Bertucci, C Boucard, V Harlay, R Appay, G Petrirena, M Barrié, O Chinot, ... Journal of the Neurological Sciences 457, 2024 | | 2024 |
| 21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE) A Bertucci, P Maby, P Rochigneux, F Legrand, C Cropet, JS Frenel, ... Immuno-Oncology and Technology 20, 2023 | | 2023 |
| 546P Early urinary potassium level is predictive of delayed methotrexate (MTX) elimination in patients with primary central nervous system lymphoma (PCNSL) A Bertucci, V Harlay, C Boucard, G Petrirena, C Campello, D Autran, ... Annals of Oncology 34, S408, 2023 | | 2023 |
| Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program DB Roufai, A Gonçalves, TDLM Rouge, S Akla, C Blonz, J Grenier, ... Oncogene 42 (17), 1417, 2023 | | 2023 |
| Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program R DB, A Goncalves, T Rouge, J Gligorov, M Saghatchian, E Renaud, ... | | 2022 |
| Prognostic value of beta 2-microglobulinin (β2MG) in cerebrospinal fluid (CSF) in primary central nervous system lymphoma (PCNSL). A Bertucci, C Boucard, V Harlay, OL Chinot, E Tabouret Journal of Clinical Oncology 40 (16_suppl), e14047-e14047, 2022 | | 2022 |
| Retrospective analysis of a cohort of patients with metastatic bladder cancer with metastatic sites limited to the pelvis and retroperitoneum treated at a single institution A Bertucci, E Bonnet, A Rollet, B Chauvet, L Cartier, R Boustany, ... European Urology 81, S1339, 2022 | | 2022 |
Francois BertucciProfesseur de Médecine - Institut Paoli-Calmettes - Aix-Marseille UniversitéAdresse e-mail validée de ipc.unicancer.fr
